SOPHiA GENETICS S.A.
SOPHNASDAQHealthcare● Active
$5.28
+$0.28(+5.50%)
Market Cap$378052393
P/E Ratio—
52W High$5.7
52W Low$2.59
SOPHiA GENETICS S.A. (SOPH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SOPH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.27
Est. -$0.23 · -16.1%
Revenue
$0.02B
Est. $0.02B · +6.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
SOPH reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.23 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.23 | -$0.27 | -16.1% | $0.02B | $0.02B | +6.3% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -$0.24 | -$0.28 | -17.9% | $0.02B | $0.02B | +5.9% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.20 | -$0.30 | -50.0% | $0.02B | $0.02B | -5.0% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.21 | $0.33 | +257.1% | $0.02B | $0.02B | -0.2% |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.21 | -$0.26 | -23.8% | $0.02B | $0.02B | +1.9% |
| — Q1 FY2025 | Mar 4, 2025 | -$0.23 | -$0.23 | +0.0% | $0.02B | $0.02B | +4.4% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -$0.24 | -$0.28 | -16.7% | $0.02B | $0.02B | -12.3% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.27
EPS Est.
-$0.23
EPS Surpr.
-16.1%
Revenue
$0.02B
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
-$0.28
EPS Est.
-$0.24
EPS Surpr.
-17.9%
Revenue
$0.02B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.20
EPS Surpr.
-50.0%
Revenue
$0.02B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.33
EPS Est.
-$0.21
EPS Surpr.
+257.1%
Revenue
$0.02B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.21
EPS Surpr.
-23.8%
Revenue
$0.02B
Q1 FY2025
Mar 4, 2025
EPS Actual
-$0.23
EPS Est.
-$0.23
EPS Surpr.
+0.0%
Revenue
$0.02B
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
-$0.28
EPS Est.
-$0.24
EPS Surpr.
-16.7%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2027 | $-0.15 | $-0.14 | $-0.14 | 1 |
| Q2 FY2027 | $-0.19 | $-0.18 | $-0.18 | 1 |
| Q1 FY2027 | $-0.21 | $-0.20 | $-0.19 | 1 |
| Q4 FY2026 | $-0.19 | $-0.18 | $-0.17 | 1 |
| Q3 FY2026 | $-0.21 | $-0.20 | $-0.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -16.1% | $5.29 | $5.07 | -4.16% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -17.9% | $4.62 | $4.10 | -11.26% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -50.0% | $5.00 | $4.68 | -6.40% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +257.1% | $3.30 | $3.42 | +3.64% |
| ▼ Q2 FY2025 | May 6, 2025 | -23.8% | $3.14 | $3.00 | -4.46% |
| ▲ Q1 FY2025 | Mar 4, 2025 | +0.0% | $3.57 | $3.10 | -13.17% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -16.7% | $3.75 | $3.75 | +0.00% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +17.9% | $4.15 | $4.06 | -2.17% |
Q2 FY2026-4.16%
Report Date
May 5, 2026
EPS Beat/Miss
-16.1%
Price Before
$5.29
Price After
$5.07
Q1 FY2026-11.26%
Report Date
Mar 3, 2026
EPS Beat/Miss
-17.9%
Price Before
$4.62
Price After
$4.10
Q4 FY2025-6.40%
Report Date
Nov 4, 2025
EPS Beat/Miss
-50.0%
Price Before
$5.00
Price After
$4.68
Q3 FY2025+3.64%
Report Date
Aug 5, 2025
EPS Beat/Miss
+257.1%
Price Before
$3.30
Price After
$3.42
Q2 FY2025-4.46%
Report Date
May 6, 2025
EPS Beat/Miss
-23.8%
Price Before
$3.14
Price After
$3.00
Q1 FY2025-13.17%
Report Date
Mar 4, 2025
EPS Beat/Miss
+0.0%
Price Before
$3.57
Price After
$3.10
Q4 FY2024+0.00%
Report Date
Nov 5, 2024
EPS Beat/Miss
-16.7%
Price Before
$3.75
Price After
$3.75
Q3 FY2024-2.17%
Report Date
Aug 6, 2024
EPS Beat/Miss
+17.9%
Price Before
$4.15
Price After
$4.06
Avg Beat Reaction-3.90%
Avg Miss Reaction-5.26%
Beat Rate3 / 8 quarters
Largest Move-13.17% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SOPH ends December
SOPHiA GENETICS S.A. (SOPH) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.27 — missing the analyst consensus of $-0.23 by -16.1%. The next SOPH earnings date is expected around September 1, 2026.
Each quarter, investors track SOPH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SOPH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SOPH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SOPH earnings · 5 questionsSOPHiA GENETICS S.A.'s next earnings report is expected around September 1, 2026. SOPH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SOPH historically reports after market close (AMC).
SOPH earnings datewhen is SOPH earningsSOPH next earnings datewhen does SOPH report earningsSOPH earnings calendar
▸ Source: FMP · SOPHiA GENETICS S.A. SEC filings · US GAAP · SOPHiA GENETICS S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026